Evidence map›Paper›PMID 37760460›Full record

ArticleCancers2023

IGF2BP3 as a Prognostic Biomarker in Well-Differentiated/Dedifferentiated Liposarcoma.

Kyle D Klingbeil, Jack Pengfei Tang, Danielle S Graham, Serena Y Lofftus, Amit Kumar Jaiswal, Tasha L Lin, Chris Frias, Lucia Y Chen, Manando Nakasaki, Sarah M Dry and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Interplay of RNA mBiomedicines · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Kyle D KlingbeilDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90049, USA.
Jack Pengfei TangUniversity of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.ORCID 0000-0003-4479-9638
Danielle S GrahamDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90049, USA.ORCID 0000-0003-4839-1250
Serena Y LofftusDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90049, USA.
Amit Kumar JaiswalDepartment of Pathology & Laboratory Medicine, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.ORCID 0000-0003-4396-8700
Tasha L LinDepartment of Medicine, Division of Hematology and Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.
Chris FriasDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90049, USA.
Lucia Y ChenDepartment of Medicine, Statistics Core, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.
Manando NakasakiDepartment of Pathology & Laboratory Medicine, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90095, USA.
Sarah M DryJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Joseph G CromptonDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90049, USA.ORCID 0000-0001-9325-2909
Fritz C EilberDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90049, USA.ORCID 0000-0003-3336-9333
Dinesh S RaoJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Anusha KalbasiDepartment of Radiation Oncology, Stanford Cancer Institute, Stanford School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0001-8692-1457
Brian E KaderaDepartment of Surgery, Division of Surgical Oncology, University of California, Los Angeles David Geffen School of Medicine, Los Angeles, CA 90049, USA.ORCID 0000-0002-5133-8656
University of California, Los Angeles · USStanford Cancer Institute

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Protein-RNA interactions in cancerR01CA264986 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Dinesh S. Rao, Jeremy Robert Sanford · 2021 to 2026
$3.7M
Targeting Radiation-Induced Myeloid Cells to Promote T cell Immunity in Undifferentiated Pleomorphic SarcomaK08CA245181 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALBASI, ANUSHA · 2020 to 2025
$1.1M
Damon Runyon Cancer Research Foundation 5K08CA245181NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1TR001881NCI NIH HHS K08 CA245181NCI NIH HHS R01 CA264986
6 · The paper itself

Abstract

backgroundAlthough IGF2BP3 has been implicated in tumorigenesis and poor outcomes in multiple cancers, its role in soft-tissue sarcoma (STS) remains unknown. Preliminary data have suggested an association with IGF2BP3 expression among patients with well-differentiated/dedifferentiated liposarcoma (WD/DD LPS), a disease where molecular risk stratification is lacking.

methodsWe examined the survival associations of IGF2BP3 via univariate and multivariate Cox regression in three unique datasets: (1) the Cancer Genome Atlas (TCGA), (2) an in-house gene microarray, and (3) an in-house tissue microarray (TMA). A fourth dataset, representing an independent in-house TMA, was used for validation.

resultsWithin the TCGA dataset, IGF2BP3 expression was a poor prognostic factor uniquely in DD LPS (OS 1.6 vs. 5.0 years,

conclusionIGF2BP3 is highly expressed in a subset of WD/DD LPS. Across independent datasets, IGF2BP3 is also a biomarker of disease progression and worse survival.

Indexed as

dedifferentiated liposarcomagene microarrayIGF2BP3IMP3liposarcomaprognostic biomarkersoft-tissue sarcomaTCGAtissue microarraywell-differentiated liposarcoma

Identifiers

PMID37760460
PMCPMC10526143
OpenAlexW4386602774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.